C
Cognoa
Consumer healthcare company that’s changing how parents assess and support their child’s development
About Cognoa
Cognoa is a healthcare technology startup that operates in the child developmental health market. The company's primary focus is on early diagnosis and intervention for children with developmental concerns, specifically autism. Their product, Canvas Dx, is the first and only FDA authorized diagnostic solution designed to diagnose or rule out autism in children aged 1.5 to 6 years. This tool allows healthcare providers to make a diagnosis within days, rather than the months or years it typically takes with traditional methods.
Read full description
Cognoa's business model is centered around providing a remote, digital evaluation service for children with developmental concerns. This service is particularly beneficial for families who live far from specialty centers or who face long waiting lists for evaluation. By offering a faster path to diagnosis and next steps, Cognoa helps to alleviate the prevalent biases in diagnoses and ensures that all children, regardless of their background, have access to timely care.
The company makes money by selling its diagnostic solution to healthcare providers. It also potentially generates revenue from partnerships with healthcare institutions and insurance companies.
Cognoa's mission is to change the status quo in child developmental health, which is currently slow, complicated, and expensive. By leveraging data and artificial intelligence, the company aims to provide an informed, rapid, and universally accessible path to care, ultimately empowering children and their families to live fulfilling lives.
At a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Palo Alto, United States
- Employees
- 41
- Open positions
- None listed
- Dealroom signal
- 78.3/100
- Industry
- Health, Kids
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, User Behavior, Mental Health, Digital Therapeutics, Tech for Biotech and Pharma, Tech for Patients, Hard Tech
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning Cognoa.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2022 | $73M | $292M | Undisclosed | — |
| SERIES AOther financing | Oct 2019 | $45M | $180M | Morningside | — |
Growth signals
Latest recorded traffic for Cognoa is 3.4K monthly website visits, down 37% over the last three months. Cognoa's team grew 2.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cognoa on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cognoa’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.